• 1
    Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355:51-65.
  • 2
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
  • 3
    Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
  • 4
    Chapman PB, Hauschild A, Robert C, et al;BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
  • 5
    Zito CR, Kluger HM. Immunotherapy for metastatic melanoma. J Cell Biochem. 2012;113:725-734.
  • 6
    Meier T, Uhlik M, Chintharlapalli S, et al. Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization. Mol Cancer Ther. 2011;10:2168-2178.
  • 7
    Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst. 1989;81:1088-1092.
  • 8
    Kirkwood JM, Gonzalez R, Reintgen D, et al. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer. 2011;117:4732-4739.
  • 9
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
  • 10
    Hill GJ 2nd, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer. 1984;53:1299-1305.
  • 11
    Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
  • 12
    Lawson DH, Gonzalez R, Weber RW, et al. 2-year overall survival (OS) results of a phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM) [abstract]. J Clin Oncol. 2008;26. Abstract 20023.
  • 13
    Hauschild A, Eggermont M, Jacobson E, O'Day SJ. Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM) [abstract]. J Clin Oncol. 2009;27(18 suppl). Abstract LBA9012.
  • 14
    Simon GR, Ilaria RL Jr, Sovak MA, et al. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2011;68:1233-1241.
  • 15
    de Alwis D, Cleverly A, Chow K, Troconiz I, Ilaria R. Tailored dosing of tasisulam sodium (LY573636 sodium) to reduce hematological toxicity and improve therapeutic index. EJC Suppl. 2010;8:92-93. Abstract 286.
  • 16
    National Cancer Institute.Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Accessed May 13, 2013.
  • 17
    Kaplan E, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958;53:457-481.
  • 18
    Gordon MS, Ilaria R Jr, de Alwis DP, et al. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71:21-27.
  • 19
    Bedikian AY, Plager C, Papadopoulos N, Eton O, Ellerhorst J, Smith T. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res. 2004;14:63-66.
  • 20
    Legha SS, Ring S, Papadopoulos N, Raber M, Benjamin RS. A phase II trial of taxol in metastatic melanoma. Cancer. 1990;65:2478-2481.
  • 21
    Einzig AI, Hochster H, Wiernik PH, et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs. 1991;9:59-64.
  • 22
    Wiernik PH, Einzig AI. Taxol in malignant melanoma. J Natl Cancer Inst Monogr. 1993;(15):185-187.
  • 23
    Zimpfer-Rechner C, Hofmann U, Figl R, et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res. 2003;13:531-536.
  • 24
    Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27:2823-2830.
  • 25
    Greco FA, Thomas M, Hainsworth JD. One-hour paclitaxel infusions: review of safety and efficacy. Cancer J Sci Am. 1999;5:179-191.
  • 26
    Onetto N, Canetta R, Winograd B, et al. Overview of Taxol safety. J Natl Cancer Inst Monogr. 1993;(15):131-139.